FDA-cleared profile

Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR

Canon Medical Systems Corporation

Vantage Galan 3T is a head and body diagnostic MRI system with noncontrast MRA and AiCE deep-learning reconstruction; K243335 also covers the PIQE image-processing workflow under the cleared release.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Vantage Galan 3T is a head and body diagnostic MRI system with noncontrast MRA and AiCE deep-learning reconstruction; K243335 also covers the PIQE image-processing workflow under the cleared release.
FDA source Exact FDA submission Checked 2026-09-03
Intended users
Qualified MRI technologists and physicians trained in magnetic resonance imaging.
FDA source Exact FDA submission Checked 2026-09-03
Care setting and population
Hospital and outpatient MRI departments operating the cleared field strength, coils, protocols, and accessories.
FDA source Exact FDA submission Checked 2026-09-03
Workflow role
MRI acquisition, reconstruction, review, and release-specific workflow support.
FDA source Exact FDA submission Checked 2026-09-03
Required input
Patient MRI signal data acquired with supported coils, pulse sequences, field strengths, and release-specific protocols.
FDA source Exact FDA submission Checked 2026-09-03
Output and human action
Cross-sectional MR images, spectra, derived measurements, and reconstructed series for professional review.
FDA source Exact FDA submission Checked 2026-09-03
Limitations
Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
FDA source Exact FDA submission Checked 2026-09-03

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243335
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
FDA source Exact FDA submission Checked 2026-09-03
Anatomy
Multi-region
FDA source Exact FDA submission Checked 2026-09-03
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-01-07
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K243335; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Deployment and data flow
Installed MRI hardware and release-specific scanner software with licensed coils, sequences, reconstruction options, and accessories.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K243335; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-03

Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.

Training and support
Only qualified mri technologists and physicians trained in magnetic resonance imaging should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-03
Monitoring and change control
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.
Public source Product family Checked 2026-09-03

Current vendor materials are product-family evidence for K243335; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K243335 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS or downstream applications; validate worklist, identifiers, series labels, geometry, measurements, routing, and archive completeness.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Field strength, coil, sequence, anatomy, population, implant, intervention, and optional-feature limits vary by model and release; map the installed configuration to the exact clearance and labeling.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K243335 reports PIQE testing in 106 unique subjects and 480 scans across three sites, with 14 board-certified radiologists and cardiologists rating body, breast, cardiac, musculoskeletal, and neurologic images. Family and product materials describe AiCE or PIQE capabilities, but reader ratings do not establish universal diagnostic sensitivity or specificity.
FDA source Exact FDA submission Checked 2026-09-03
Reported sensitivity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
Not applicable Not applicable Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

PIQE validation subjects

106 subjects

PIQE image-quality validation in Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR.

Tested version: Vantage Galan 3T with AiCE and PIQE

PIQE scans

480 scans

PIQE image-quality validation in Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR.

Tested version: Vantage Galan 3T with AiCE and PIQE

PIQE validation sites

3 sites

PIQE image-quality validation in Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR.

Tested version: Vantage Galan 3T with AiCE and PIQE

PIQE readers

14 readers

PIQE multi-reader evaluation in Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR.

Tested version: Vantage Galan 3T with AiCE and PIQE

K243335 FDA performance package for Vantage Galan 3T, MRT-3020, V10.0 with AiCE Reconstruction Processing Unit for MR

Manufacturer MRI system, AiCE or PIQE image-processing, image-quality, and multi-reader validation · 106 unique subjects, 480 scans, 3 sites, and 14 board-certified radiologists or cardiologists across body, breast, cardiac, MSK, and neuro imaging

exact submission · Tested version: Vantage Galan 3T with AiCE and PIQE · Sponsor or vendor study

K243335

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-03

No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
Public source Not applicable Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
1 exact-submission FDA recall record in the 2026-09-02 openFDA snapshot identify K243335. Affected model, version, unit, correction, and current manufacturer instructions still require local confirmation. FDA recall Z-0327-2026 is Open, Classified for VANTAGE GALAN 3T. CMSC Model: MRT-3020/U7. Model Number: MEXL-3020/B7.. FDA reason: Affected system contains components that do not meet the required distance between electrodes for compliance with the IEC 60601-1 standard for medical electrical equipment. FDA action: Cannon Medical began notifying consignees via email on about 10/16/2025. Consignees were instructed that a representative of Canon Medical Systems USA will contact them to schedule a time to replace the relevant parts. If the message "Gradient power supply error is displayed before the replacement is performed, immediately stop using the system and contact your service representative. Consignees were requested to complete and return the provided response form
FDA source Exact FDA submission Checked 2026-09-04

Each published event was manually matched to the exact FDA submission and affected product or version; a recall does not establish an AI-algorithm defect or current site exposure unless the event states that scope.

recall: Z-0327-2026

Open, Classified

2025-10-24

Exact native submission match in the checked openFDA snapshot. Published as a product, system, labeling, or postmarket issue; do not infer an AI-algorithm defect unless the FDA record says so. Confirm affected model, version, units, corrective action, and completion status locally.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
25Fields reviewed
11Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA decision materials were reviewed for identity, indication, users, workflow, limitations, and submitted performance. Current vendor material is labeled product-family context where it does not establish the exact release. PubMed and ClinicalTrials.gov results are retained as candidate evidence with version applicability pending; CMS reimbursement context and exact-identifier openFDA postmarket results were also checked. Pricing, final security architecture, contracted services, enabled options, and local interoperability remain organization-specific evidence. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. 1 FDA recall candidate was manually reviewed: 1 published and 0 rejected as a neighboring or otherwise inapplicable version. Native FDA recall identifiers produced 1 postmarket candidate record; 1 has been reviewed (1 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K260746

S-scan Open (100001800)

Esaote, S.p.A.

S-scan Open is an Esaote MR system for diagnostic image acquisition, reconstruction, display, and professional interpretation within the labeled scanner, coil, sequence, and...

Modality
MRI
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K252379

AIR Recon DL

Ge Medical Systems, LLC

AIR Recon DL adds a deep-learning phase-correction and reconstruction option to supported GE 1.5T, 3T, and 7T MR workflows for all labeled anatomies and ages to reduce noise or...

Modality
MRI
Anatomy
Multi-region
Decision
2025-12-23